WO2001002094A1 - Dispositif matrice a microcircuit integre destine a l'amplification et a la caracterisation d'acides nucleiques - Google Patents

Dispositif matrice a microcircuit integre destine a l'amplification et a la caracterisation d'acides nucleiques Download PDF

Info

Publication number
WO2001002094A1
WO2001002094A1 PCT/EP2000/006103 EP0006103W WO0102094A1 WO 2001002094 A1 WO2001002094 A1 WO 2001002094A1 EP 0006103 W EP0006103 W EP 0006103W WO 0102094 A1 WO0102094 A1 WO 0102094A1
Authority
WO
WIPO (PCT)
Prior art keywords
chamber
chip
probes
chamber body
capillary gap
Prior art date
Application number
PCT/EP2000/006103
Other languages
German (de)
English (en)
Other versions
WO2001002094A8 (fr
Inventor
Ralf Ehricht
Thomas Ellinger
Jens Tuchscherer
Eugen Ermantraut
Siegfried Poser
Torsten Schulz
Original Assignee
Clondiag Chip Technologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clondiag Chip Technologies Gmbh filed Critical Clondiag Chip Technologies Gmbh
Priority to CA002379125A priority Critical patent/CA2379125C/fr
Priority to EP00952983A priority patent/EP1192007B1/fr
Priority to AT00952983T priority patent/ATE264718T1/de
Priority to IL14722700A priority patent/IL147227A0/xx
Priority to AU65599/00A priority patent/AU768113B2/en
Priority to DE50006164T priority patent/DE50006164D1/de
Publication of WO2001002094A1 publication Critical patent/WO2001002094A1/fr
Publication of WO2001002094A8 publication Critical patent/WO2001002094A8/fr
Priority to IL147227A priority patent/IL147227A/en
Priority to US10/038,284 priority patent/US7888074B2/en
Priority to HK02106805.0A priority patent/HK1046381A1/zh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/30—Micromixers
    • B01F33/3031—Micromixers using electro-hydrodynamic [EHD] or electro-kinetic [EKI] phenomena to mix or move the fluids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/14—Process control and prevention of errors
    • B01L2200/142—Preventing evaporation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0636—Integrated biosensor, microarrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0415—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic
    • B01L2400/0418—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic electro-osmotic flow [EOF]

Definitions

  • the invention relates to a device for the duplication and characterization of nucleic acids.
  • DNA deoxyribonucleic acid
  • PCR polymerase chain reaction
  • Duplicate 15 clone the PCR products (insert them into a carrier molecule and insert them into a microorganism), amplify the crimped PCR products in microorganisms and isolate the amplified PCR products (Sambrook, J; Fritsch, EF and Maniatis, T ., 1989, Molecular cloning: a laboratory manual 2nd edn.
  • the one-step duplication by PCR is relatively fast, enables a high sample throughput in small batch volumes through miniaturized methods and is complete
  • thermocyclers for carrying out the PCR.
  • thermal cyclers are described which consist of capped chambers which hold the samples.
  • US Pat. No. 5,856,174 discloses a system with which it is possible to pump sample liquids back and forth between, for example, three miniaturized chambers.
  • the PCR is carried out in one chamber of this system, a workup reaction is carried out in the next and the reaction products are detected in the third, for example with a DNA chip.
  • the PCR chamber is a standard tube, as is well described in the literature (S. Poser, T. Schulz, U. Dillner, V. Baier, JM Köhler, D. Schimkat, G. Mayer, A. Siebert; Chip elements for fast thermocycling, Sensors and Actuators A, 1997: 62, 672-67).
  • the genetic characterization for example for the identification and taxonomic classification of microorganisms, is currently carried out on the basis of DNA-DNA hybridization studies, comparing rRNA gene sequences (for example by means of the 16S or 23 S rRNA gene segments) after the sequencing of these segments and on the basis of of restriction fragment length polymorphism (RFLP) or PCR tests with specific primers using gel electrophoretic separation and detection of the restriction or PCR products (TA Brown, 1996, genetic engineering for beginners, Spektrum Akademischer Verlag Heidelberg, Berlin Oxford).
  • RFLP restriction fragment length polymorphism
  • the known RFLP studies are based on an individual-specific distribution of restriction endonuclease interfaces, which relates to DNA sequence differences in the area of genomic DNA, which has a high degree of homology to a labeled DNA probe used for hybridization (TA Brown, 1996, Genotechnologie für beginnerers, Spectrum Academic Publishing House Heidelberg, Berlin Oxford).
  • HLA diagnostics human leukocyte antigen
  • immunology prior to transplantation or transfusion cf. Cesbron A., Moreau P., Milpied N., Muller JY., Harousseau JL ., Bignon JD., "Influence of HLA-DP mismatches on primary MLR responses in unrelated HLA-A, B, DR, DQ, Dw identical pairs in allogeneic bone marrow transplantation" Bone Marrow Transplant 1990, Nov 6: 5, 337- 40 or Martell RW., Oudshoom M., May RM., Du Toit ED., "Restriction fragment length polymorphism of HLA-DRw53 detected in South African blacks and individuals of mixed ancestry" Hum.
  • the isolation of genomic DNA includes the Restriction endonuclease cleavage of the DNA, separation of the DNA fragments, transfer and immobilization of the DNA fragments, preparation and labeling of the hybridization probes, hybridization, detection as well as correlation and interpretation.
  • the disadvantage of this previously not automatable examination is that such an analysis is very labor-intensive and time-consuming (it takes 5 to 10 working days) and has a low sample throughput (a worker only typed up to 50 samples in parallel). so that it is very expensive.
  • RNA molecules ribonucleic acid molecules
  • Gene probes are single-stranded nucleic acid molecules of known nucleotide base sequence with an optimal length of 100 to 300 bases, which lead specifically to single-stranded nucleic acid sections, e.g. a gene, to a double-stranded nucleic acid pairing and mostly with a non-radioactive or radioactive reporter element (marker), e.g.
  • a radionucleotide dye which serve the detection of the gene probes.
  • hybridization In hybridization, a distinction is made between the hybridization of probes with isolated single-stranded nucleic acid (DNA or RNA) and the so-called in situ hybridization (on-site hybridization in tissues, cells, cell nuclei and chromosomes), in which the gene probe is spread to one another in the cell (Single-stranded) nucleic acid (DNA or RNA) couples (Leitch, AR, Schwarzacher, T., Jackson, D. and Leitch IJ, 1994, in situ hybridization, Spektrum Akademischer Verlag Heidelberg, Berlin Oxford). With this in situ hybridization it is particularly important that the target sequence and the tissue morphology are preserved and that the preserved tissue is permeable to the probe and the detection reagents. This permeability is not always present, which is a disadvantage of this method.
  • nucleic acid target and nucleic acid probe molecules Essential for the hybridization is the presence of single-stranded nucleic acid target and nucleic acid probe molecules, which is mostly done by heat denaturation, as well as the selected optimal stringency (setting of the parameters: temperature, ionic strength, concentration of helix-destabilizing molecules), which ensures that only probes with almost perfectly complementary ones (corresponding) sequences remain paired with the target sequence (Leitch, AR, Schwarzacher, T., Jackson, D. and Leitch IJ, 1994, in situ hybridization, Spektrum Akademischer Verlag Heidelberg, Berlin Oxford).
  • rRNA ribosomal RNA
  • rDNA ribosomal RNA
  • the rDNA contains flanking sequence sections that are highly conserved within the respective organism kingdom. Primer sequences directed against these sections can be used for species-independent amplification of the rDNA (G. Van Camp, S. Chapelle, R.
  • Metab, 1999; 66: 205-211) describe a method in which rDNA is amplified from clinical bacterial isolates lysed on filter spots by using universal primers and subsequently identified by hybridization with specific probes. This process is sensitive; however, the number of species to be detected is also relatively narrow.
  • the invention is based on the object of specifying a device for the duplication and characterization of nucleic acids which enables an almost simultaneous duplication and characterization with a high sample throughput and thus avoids the disadvantages of the prior art.
  • the essence of the invention is that the device spatially combines the PCR and the parallel hybridization against chip-bound nucleic acid in a temperature and flow controllable cell (chamber).
  • the interior of the chamber carries a chip that generates a capillary gap between the chamber bottom and the detection surface of the chip, which receives the sample liquid, the sample liquid being mixed by an induced electroosmotic flow.
  • the chamber around the capillary gap and the chip advantageously forms a gas reservoir through which a gas reservoir nose leads to the capillary gap leads, which separates an inlet from an outlet, so that the samples can be injected via the inlet, pass from the inlet into the capillary gap due to the capillary forces and can be removed from the latter via the outlet.
  • the capillary gap When the capillary gap is filled, an air gap is generated as a ring around the chip stored in the chamber and the capillary gap (which serves as a sample reservoir) due to surface tension effects, so that the chip and the capillary gap are thermally insulated from the chamber body, which leads to the fact that the Samples in the chamber gap can be quickly heated and cooled by heating and cooling elements, which, together with temperature sensors and electrodes, are placed on a chamber support, which holds the chamber and is in heat-conducting contact with it over the chamber floor. Because the capillary gap serves as a sample reservoir, the evaporation rate of the sample liquid is greatly reduced even at temperatures near the boiling point of the sample liquid, since the sample can only evaporate over the edge of the capillary gap.
  • the capillary gap (the sample reservoir) is the location of the nucleic acid amplification in the sample liquid by PCR with specific primers and the genetic characterization of the sample.
  • the labeled PCR products are fished out of the sample liquid by the immobilized specific probes, which are bound on the nucleic acid chip.
  • the chamber and the chip are optically transparent and, because of their design, enable the on-line detection of the marking signal of the PCR products bound to the probes.
  • the device according to the invention has the advantage over the previously used methods that a maximum genetic typing using specific probes can be automated in a minimal diagnosis time with minimal sample volumes and is possible with a high sample throughput in a temperature and flow controllable cell, with PCR being used to highlight the diagnosis relevant gene structures against a sequence background and the almost simultaneous, parallel hybridization of the PCR products against the chip-bound nucleic acid results in a specific detection.
  • the device according to the invention is used, for example, for the simultaneous detection of different microbial pathogens (for example based on the 16S or 23 S rRNA analysis), the screening for resistance of individual disease-causing microorganisms or a genomic typing of diagnostically relevant allele structures of eukaryotic cells, the parallel detection is made possible by the chip with its different probes specific to the different target sequences.
  • microbial pathogens for example based on the 16S or 23 S rRNA analysis
  • the parallel detection is made possible by the chip with its different probes specific to the different target sequences.
  • FIG. 1 a basic representation of a possible embodiment of a device according to the invention for the duplication and characterization of nucleic acids
  • FIG. 2 a cross section along the plane AA according to FIG. 1
  • FIG. 3 a plan view of the device according to FIG. 1 .
  • Fig. 4 a schematic representation of the view of the bottom of the
  • FIG. 5 shows a cross section along the plane B-B according to FIG. 4
  • FIG. 6 a schematic representation of the top view of the chamber support of the device according to FIG. 1,
  • FIG. 7 a cross section along the plane CC according to FIG. 6,
  • FIG. 8 a schematic representation of a possible quadrupole arrangement on the chamber support of the device according to FIG. 1,
  • FIG. 9 a cross section along the plane DD according to FIG .8th ,
  • FIG. 10a a schematic representation of a possible positioning of a sample liquid within the device according to FIG. 1
  • FIG. 10b a cross section along the plane E-E according to FIG. 10a
  • FIG. 11 a schematic block diagram of a possible installation of the device according to FIG. 1 in an analysis system
  • FIG. 12a an indication of the dimensions of a device according to FIG. 1 in millimeters
  • 12b an indication of the dimensions of a device according to FIG. 2 in millimeters
  • FIG. 12c an indication of the dimensions of a device according to FIG. 3 in millimeters
  • FIG. 13 a schematic representation of the optical beam path through the device according to FIG 1
  • FIG. 14 a schematic illustration of an embodiment of a chip of the device according to FIG. 1
  • FIG. 15 a schematic illustration of secondary and tertiary amplification products of the chip according to FIG. 14.
  • the device 20 shown in FIG. 1 for the duplication and characterization of nucleic acids consists of a chamber body 1 and a chamber carrier 5.
  • the chamber body 1 is provided with a bearing surface 4, via which it is sealingly connected to the chamber carrier 5, so that a sample chamber 3 is trained.
  • This sample chamber 3 consists of a gas reservoir 6 and a capillary gap 7 and is provided with at least one inlet 81 and at least one outlet 82.
  • the inlet 81 and the outlet 82 lead into the sample chamber 3 and are spaced apart by an intermediate gas reservoir nose 9 of the gas reservoir 6.
  • the chamber body 1 which is in a non-detachable sealing connection, for example by adhesive bonding or welding to a chamber carrier 5, which is not shown in detail, holds a chip 2, for example a nucleic acid chip.
  • This chip 2 which carries detection surfaces 12 in the form of spots 13, is held in the chamber body 1 in such a way that the detection surfaces 12 in the form of spots 13 face the surface of the chamber carrier 5 opposite and through the edge 42 of the chamber body 1 from the chamber carrier 5 evenly are positioned so that the chip 2 and the chamber carrier 5, as shown in FIG. 2, generate the capillary gap 7, which serves as a sample reservoir.
  • This capillary gap 7 receives the sample liquid 19.
  • the chamber body 1 consists, for example, of optically transparent plastic or glass
  • the sample chamber 3 which represents a space for filling the sample liquid 19, by milling and the inlet 81 and the Outlet 82, which are routes for the sample liquid, can be introduced into the chamber body 1 by drilling.
  • the nucleic acid chip 2 consists of an optically transparent support, the material of which can be, for example, silicon or glass, and of nucleic acid molecules of a specific sequence (eg probes) immobilized on this support.
  • the sample chamber 3 comprises the gas reservoir 6 and the capillary gap 7, gas and air bubbles collecting in the gas reservoir 6 when filling the sample liquid 19 due to surface tension effects, so that the chip 2 and the capillary gap 7 are thermally insulated from the chamber body 1.
  • the inlet 81 and the outlet 82 serve to direct the sample liquid 19, which enables the sample chamber 3 to be filled and emptied, and thus also to fill and empty the capillary gap 7 as a result of the capillary forces acting.
  • the inlet 81 and the outlet 82 which can for example run side by side as shown in FIG. 1, are spatially separated from one another by a gas reservoir nose 9, so that the sample liquid 19 is prevented from flowing from the inlet 81 to the outlet 82 without entering the Capillary gap 7 to arrive.
  • the chamber support 5, which is optically transparent and has good heat conductivity, consists, for example, of glass and, as shown in FIGS. 4, 6 and 8, is provided with means for applying temperature 17, for example in the form of miniaturized heaters, and with miniaturized temperature sensors 16 and electrodes of a quadropole 18 so that temperature control of the sample liquid 19 and mixing of the sample liquid 19 by an induced electroosmotic flow is made possible.
  • the chamber body 1 can be provided with the means for applying temperature 17 and the miniaturized temperature sensors 16 and the electrodes of the quadropole 18.
  • the temperature sensors 16 can, for example, be designed as nickel-chrome thick-film resistance temperature sensors.
  • the length of the temperature sensor 16 is, for example, in the case that the chamber support 1 has an area of 8 x 8 mm and the chip 2 has an area of 3 x 3 mm or less, 10.4 mm and the width of the temperature sensor 16 in this example 50 ⁇ m, so that the resistance at 20 ° C is 4 kOhm and the temperature coefficient TK R at 0 ° C is 1500 ppm.
  • the temperature sensors 16 can also be designed as optically transparent thin layers.
  • the means for applying temperature 17 can, for example, be designed as a nickel-chrome thick-film resistance heater.
  • the means for applying temperature 17 have a length of 2.6 mm and a width of eight individual webs, each 50 ⁇ m wide, so that the resistance at 20 ° C. is 300 ohms.
  • the means for applying temperature 17 can also be designed as optically transparent thin layers.
  • the quadrupole 18 can be designed, for example, as gold-titanium electrodes. In the dimensions of the previous example, these electrodes have a length of 2.2 mm and a width of 0.5 mm.
  • the quadropole serves to induce an electroosmotic flow, which leads to the mixing of the sample liquid 19 in the sample chamber 1.
  • the quadrupole 18 can also be designed as an optically transparent thin layer.
  • the chamber body 1 which is in rigid, non-detachable connection with the chamber carrier 5 via the support surface 4.
  • This connection can be made, for example, by gluing.
  • the chamber support 5 and the chamber body 1 are connected to one another by fusion or are manufactured in one piece.
  • the capillary gap 7 which serves as a sample reservoir, which due to its capillary action is capable of absorbing sample liquid from the sample chamber 3.
  • the inlet 81 and the outlet 82 lead into the gas reservoir 6 of the sample chamber 3, so that sample liquid 19 can be filled through the gas reservoir 6 into the capillary gap 7 through the inlet 81 and can be discharged via the outlet 82.
  • the chip 2 consists of optically transparent or transparent material, such as glass, so that optical and photometric evaluations, such as fluorescence measurements, of the detection surface 12 are possible via a conical opening in the chamber body 1, the recess 11 are.
  • Fig. 3 shows the inlet 81 and the outlet 82 and the recess 11 through which the detection surface 12 with spots 13 of the chip 2 are optically accessible. This optical accessibility enables the above. optical and photometric evaluations of the signals emanating from the detection surface 12, in the example the fluorescence signals not shown.
  • the means for applying temperature 17 including conductor tracks 1517 and connection surfaces 1417, located on the underside of the transparent chamber support 5.
  • the means for applying temperature 17 consist of eight individual microstructured ones connected in parallel
  • the resistance lines 171 of the means for applying temperature 17, which can be acted upon with a different, predefined temperature, have dimensions such that the above. optical accessibility of the detection surfaces 12 of the chip 2 is ensured.
  • FIG. 5 shows the positioning of the means for applying temperature 17 on the side of the chamber carrier 5 which faces away from the chamber body 1 and which carries the chamber body 1 with the chip 2 held thereon.
  • 6 shows a temperature sensor 16 mounted on the upper side of the transparent chamber support 5, including conductor tracks 1516 and connection surfaces 1416.
  • the temperature sensor 16 is mounted around the detection surface 12 of the chip 2, so that the aforementioned optical accessibility of the detection surface 12 is ensured.
  • the temperature sensor 16 is electrically insulated from subsequent elements of the device 20 and from the sample liquid 19 by a passivation layer (not shown in the figure).
  • FIG. 8 shows a quadrupole 18, including associated conductor tracks 1518 and connection pads 1418, applied to the passivation layer of the temperature sensor 16, which is not shown in detail.
  • the quadrupole 18 is in electrically conductive contact with the sample liquid 19, so that the alternating application of a voltage of +1 V at two electrodes 181 of the quadrupole 18, a swirl which can be induced by the electroosmotic flow can be caused in the capillary gap 7 filled with sample liquid 19.
  • the swirl conditions change.
  • the sample liquid 19 is effectively mixed.
  • the applied low voltage of only one volt prevents the sample liquid 19 from undergoing electrochemical changes in the capillary gap 7 and, for example, gas bubbles forming.
  • the quadrupole 18 is, as shown in this figure, designed so that the optical accessibility of the detection surface 12 is ensured. Alternatively, the quadrupole 18 can also be designed as an optically transparent thin layer.
  • FIG. 9 shows the positioning of the quadrupole 18 on the surface side of the chamber carrier 5 facing the chamber body 1.
  • FIGS. 10 a and b show schematically the sample liquid 19 stored in the capillary gap 7 between the chamber body 1 and the chamber carrier 5.
  • any air bubbles (not shown in detail) can be derived from the capillary gap 7 into the gas reservoir 6 of the sample chamber 3.
  • the evaporation rate of the sample liquid 19 is greatly reduced even at temperatures near the boiling point, since the sample liquid 19 can only evaporate over the edge of the capillary gap 7.
  • sample liquid 19 is low (in the ⁇ l range) sample reservoir 7, since the capillary gap 7 forms only a small volume, which means that the sample volumes required are very small. Due to the described good thermal insulation of the chip 2 and the sample liquid 19 in relation to the chamber body 1 and the small volume of the sample liquid 19, the usual ones for microthermal cyclers, which Posner et al. heating and cooling rates described (S. Poser, T. Schulz, U. Dillner, V. Baier, JM Köhler, D. Schimkat, G. Mayer, A. Siebert; Chip elements for fast thermocycling, Sensors and Actuators A, 1997 , 62: 672-675).
  • the temperature homogeneity of the sample liquid 19 and the heat input into the sample liquid 19, which is positioned in the capillary gap 7 between the chip 2 and the temperature-controllable chamber support 5, are to a large extent ensured due to the large heating surface-to-sample volume ratio.
  • FIG 11 shows the installation of the device 20 for duplication
  • the analysis system 200 consists of a temperature regulator 21, one
  • the device 20 is located above the inlet 81 and the outlet 82 directly to the conditioner 27 and the waste vessel 26 and via the electrical lines 23 ⁇ and 24 directly to the temperature controller 21 and the mixing control 22 in connection, the temperature controller with the temperature sensors 16 and the means for applying temperature 17 and the mixing control the Quatrupol 18 is coupled.
  • the sample liquid 19 can be pipetted into the total inlet 25 via the automatic pipetting device 37 from microplates not shown in detail.
  • the sample liquid 19 can be conducted through the connecting hoses 30 into the conditioner 27, the conditioner 27 serving to process the sample liquid 19 (for example pH adjustment and Filter out interfering substances).
  • the buffer liquids and reaction solutions for this workup can be supplied from the storage containers 29, which are in a liquid-conducting connection with the conditioner 29.
  • the automatic pipetting device 37 and the conditioner 29 are connected to the conditioner control 31 and the automatic control 32 via the electrical lines 33 and serve to control and regulate them.
  • the inlet 81 and the outlet 82 of the chamber body 1, which lead into the gas reservoir 6, serve for the liquid line from the conditioner 29 via the capillary gap 7 to the waste 26.
  • the sample liquid 19 can be tempered and mixed in the area of the capillary gap 7 by means of the temperature controller 21 and the mixing control 22.
  • the capillary gap 7 is therefore the site of the amplification and characterization of a nucleic acid, in the example the target DNA.
  • Figures 12a to c show an example of an embodiment of the device 20 that the chamber body 1 has a length and width of 8 mm and a height of 3 mm, the gas reservoir length and width of 5.4 mm and a height of 0.5 to 0.8 mm, the chamber support 5 has a thickness of 0.9 mm, the recess 11 on its side facing the chip 2 has a diameter of 2.8 mm and the inlet 81 and the outlet 82 have a diameter of 0.5 mm have, the inlet 81 and the outlet 82, and the recess 11 with respect to the chamber support 5 have an inclination of 70.
  • the device 20 shows the optical beam path through a further embodiment of the device 20, in which the support surface 4 is detachably and sealingly connected to the chamber carrier 5 via an additional sealing surface 43, for the dark field fluorescence image of the detection surface 12 chips 2.
  • the excitation light is directed by the dark field mirror 38 onto the detection surface 12 along the excitation light beam path 39.
  • the fluorescent light emanating from the detection surface 12 is directed along the detection light beam path 40 onto a microscope objective 41.
  • the distance between the dark field mirror 38 and the detection surface 12 is approximately 4.6 mm and the distance between the detection surface 12 and the microscope objective 41 is approximately 22.0 mm.
  • the optical readout of the interaction signal between the target DNA 50 shown in FIG. 14 and the probe DNA 56, 57, 58, 59 on the surface of the chip 2 can take place online due to the construction of the device 20.
  • the chip 2 is held in the chamber body 1 in such a way that it can be irradiated by light in a wide solid angle, so that the hybridization can be tracked online or in situ by means of the marked probes 56, 57, 58, 59, for example fluorescence measurements.
  • the arrangement and size of the temperature sensor 16 and the quadrupole 19 is designed in such a way that the beam path for the online detection or the subsequent in situ detection is not disturbed and the detection of the interactions on the spots 13 by all forms of optical detection or spectroscopy (eg photometry, differential photometry, confocal fluorescence measurement, dark field fluorescence measurement, transmitted light fluorescence measurement, incident light fluorescence measurement etc.) can be evaluated, whereby the label 60 and measurement method must be coordinated.
  • optical detection or spectroscopy eg photometry, differential photometry, confocal fluorescence measurement, dark field fluorescence measurement, transmitted light fluorescence measurement, incident light fluorescence measurement etc.
  • Fig. 14 shows the schematic representation of the chip 2, which bears the primers 54 (A) and 53 (B '), these showing the specific sequence region of the target DNA 50, that is to say the sequences A, X, S1, X, B and B ', X, S1', X, A '.
  • sequences A and B or A 'and B' define the region of the target DNA 50 or the single-stranded AB target DNA 51 and A'B 'target DNA 52 which is identical for all species Example immobilized via spacers 55, probes 56, 57, 58 and 59, which carry sequences which are specific for the target DNA 50 of a specific origin, ie in the example shown only the probes 56 and 57 hybridize with the sequences S1 and S1 'to the amplification products of the target DNA 50 (shown in Fig. 15). In contrast, no hybridization takes place on probes 58 and 59 with sequences S2 and S2 '.
  • the primers 53 and 54 carry, for example, a fluorescent label 60 which can be incorporated into the secondary amplification products 61 and 62 as a result of the amplification process, as a result of which the hybridization to the probes 56 and 57 can be detected during amplification by means of fluorescence measurement, so that the decision can be made whether the target DNA 50 between the sequence areas A and B or A 'and B' has the sequence S1 or S 1 'and / or the sequence S2 or S2'. Since the probe sequences can be specific for a particular species, for example, this method can be used to provide evidence of the presence of a particular species in a sample.
  • FIG. 15 shows the schematic representation of the secondary and tertiary amplification products 61, 62 and 63 which can be generated by means of the device 20.
  • the amount of secondary amplification products 61 and 62 is almost doubled with each cycle from the second reaction cycle within the capillary gap 7, so that the concentration of secondary amplification product is sufficient after a few cycles to hybridize to the probes 56, 57 immobilized on the spots 13, with an extension of the Probes 56, 57 complementary to the secondary amplification product 61, 62 takes place.
  • This tertiary amplification product 63 from probes 56, 57 and secondary amplification product 61, 62 can be detected, for example, by means of a label 60, which is coupled to the primers 53, 54 used, by means of fluorescence detection.
  • the chip 2 of the device 20 is a DNA chip in this example and serves, during or after the DNA amplification, for the detection of the amplification products and possibly also for the provision of solid-phase coupled DNA primers (Fig. 14 and 15).
  • a sequence S1 which is specific for a species for example Escherichia coli
  • the thermal amplification process for example PCR
  • the application range can be expanded by using several pairs of primers 53, 54.
  • the fluorescence detection of the tertiary amplification products 63 is carried out by means of fluorescent labeling 60 of the primers 53, 54.
  • Other types of labeling such as intercalators, radioisotopes, FRET systems, fluorescence-labeled nucleotides, etc., are not thereby excluded.
  • the molecular biological process taking place in the device 20 will be described below with reference to FIGS. 14 and 15.
  • the target DNA 50 originating from a biological sample is added to the sample reservoir (the capillary gap) 7 together with primers 53, 54, which can be labeled 60.
  • the spots 13 of the chip 2 on the detection surface 12 carry spacer 55 probe DNA with sequences S1, S1 ', S2, S2' etc., which are characterized in that they can be complementary to those which occur in the target DNA 50.
  • the target DNA contains 50 sequences that are complementary to probes 56 and 57. Each sequence S1, S1 'and S2, S2' etc.
  • S 1 and S 1 ' are specific for the Bacillus cereus pathogen, S2 and S2' for the Campylobacter jejuni pathogen etc. Only the Bacillus cereus pathogen is in a stool sample , after the sample has been properly processed, there will be a target DNA 50 in the sample liquid which only contains the sequences Sl and Sl '. In order to make them detectably hybridize on the detection surface 12, the number of copies of target DNA 50 must generally be increased significantly.
  • a noise-suppressing, specific DNA amplification method is therefore carried out in the sample reservoir (capillary gap) 7.
  • two primers 53, 54 with sequences A and B ', which are the same for all pathogens, are selected, which frame all possible pathogen-specific probe sequences (S1, S2, S3 ...) (as in Fig. 14) Sequences Sl and Sl 'are framed by sequences A and B').
  • the target DNA 50 is denatured at approx. 90 ° C
  • the primers 53, 54 aneal at approx. 65 ° C at B or A 'and it becomes a primer at approx.
  • the product obtained is then the primary amplification product with the sequence A, X, S 1, X, B, Y or B ', X, S 1', X, A ', Y.
  • the cycle of denaturation, anal and extension is repeated, whereupon the secondary amplification product 61, 62 (see FIG. 15) is obtained.
  • a second application example describes a parallel detection of bacterial pathogens in stool samples:
  • the chip 2 of the device 20 is a DNA chip and serves for the parallel detection of several bacterial pathogens in human or animal stool samples.
  • the total DNA from each stool sample is isolated using standard techniques (eg using the Qiagen kit provided for this).
  • the DNA is taken up in a volume of a standardized, optionally commercially available buffer system suitable for use in the device 20, in which a PCR amplification can be carried out.
  • this contains at least one thermostable polymerase, an optionally isomolar mixture of the four natural deoxynucleotide triphosphates, a divalent salt, optionally components to increase the effectiveness of the PCR, and building blocks for labeling the PCR products (e.g. fluorescence-biotin or similarly labeled deoxynucleotide triphosphates ).
  • a chip 2 is used for the detection of the organisms, on the surface of which oligonucleotide probes 56, 57, 58, 59 are immobilized, which are complementary to one or more variable regions of the 16S rRNA genes and / or the 23 S rRNA genes and / or the inner genetic areas between 16S and 23 S rRNA genes of different organisms to be detected.
  • the probes 56, 57, 58, 59 are directed, for example, against one or more of the corresponding sequences from Aeromonas spec and / or Bacillus cereus and / or Campylobacter jejuni and / or Clostridium difficile and / or Clostridium perfringens and / or Plesiomonas shigelloides and / or Salmonella spec. and / or Shigella spec. and / or Staphylococcus aureus and / or Tropheryma whippelii and / or Vibrio cholerae and / or Vibrio parahaemolyticus and / or Yersinia enterocolitica.
  • the oligonucleotide probes 56, 57, 58, 59 are arranged in spots 13 so that each individual spot 13 contains a multiplicity of oligonucleotide probes (e.g. probe 56) of the same sequence.
  • the probes 56, 57, 58, 59 are immobilized either at their 3 'end or at the 5' end or at an internal position, the 3 'end of the probes 56, 57, 58, 59 possibly being e.g. is blocked by amination so that it cannot serve as a substrate for DNA polymerases.
  • each of the probes has a high sequence specificity for the organism to be detected and on the other hand there are motifs in the genomes of the germs at a short distance from the binding site of the specific probes all or for groups of the organisms to be detected have the same sequence.
  • Universal primers 53, 54 are directed against these motifs and are suitable for PCR amplification of a sequence section which contains the binding site of the probes immobilized on chip 2 in all organisms to be detected. These primers 53, 54 are added to the DNA isolated from the stool sample and taken up in the amplification solution (sample liquid 19). Optionally, the primer 53, 54, which specifies the synthesis of the strand which contains the sequence complementary to the sample immobilized on the chip 2 during the subsequent PCR amplification, can be added as a labeled component.
  • the amplification mixture is filled into the device 20 provided with a chip 2 as described.
  • the solution in the device 20 is subjected to a cyclic temperature regime, so that the target DNA 50 is amplified according to a typical PCR mechanism and, if necessary, simultaneously labeled.
  • a hybridization step in which the target sequences amplified with the universal primers 53, 54 hybridize with the specific probes 56, 57, 58, 59 immobilized on the chip 2.
  • a rinsing step follows in which DNA molecules which are not linked to the chip and are bound non-specifically are removed.
  • Organisms present in the stool sample are identified by marking the sample spots 13 specific to them on the chip 2.
  • sample liquids 19 In order to obtain sample liquids 19 from stool samples or tissue, for example, a large number of processing steps are necessary. Cells have to be disrupted, proteins, lipids and solids have to be separated and the DNA has to be processed and purified. The enzymes, primers and other substances necessary for the use of the device must also be supplied to the sample liquid 19. These steps can be carried out by installing the device 20 for the multiplication and characterization of nucleic acids in the analysis system 200, including pumps and valves 28 which move and control the liquids, filters and reaction chambers (conditioners 27) in which the individual process steps are carried out one after the other and consist of preparation containers 29, which supply the chemicals required for this purpose (shown in FIG. 11), and carry them out automatically and continuously.
  • pumps and valves 28 which move and control the liquids, filters and reaction chambers (conditioners 27) in which the individual process steps are carried out one after the other and consist of preparation containers 29, which supply the chemicals required for this purpose (shown in FIG. 11), and carry them out automatically and continuously.
  • the samples are filled by a pipetting robot 37 from a standard delivery system (not shown in detail) into the total inlet 25 for conditioning.
  • the samples processed by the analysis system 200 reach the device 20 via the inlet 81, so that the amplification and characterization of nucleic acids of the samples can be carried out automatically.
  • the entire process is monitored by a control computer 35, which is connected to electronic controllers and control devices 21, 22, 31, 32 via a computer bus 36.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Clinical Laboratory Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Fluid Mechanics (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un dispositif d'amplification et de caractérisation d'acides nucléiques qui permette une amplification et une caractérisation quasiment simultanées avec un rendement de prélèvement élevé, ce qui permet de remédier aux inconvénients de l'état de la technique. Ce dispositif est constitué d'un corps chambre (1) qui présente un évidement dont la bordure porte de façon hermétique une puce (2) optiquement transparente. Cette puce (2) porte des acides nucléiques à différents endroits (13) d'une face de détection (12). De plus, le corps chambre (1) est posé, par une surface de pose (4), de façon hermétique sur un support de chambre (5) optiquement transparent, de telle façon qu'une fente capillaire (7), pouvant être remplie d'un liquide de prélèvement, est formée entre la face de détection (12) de la puce (2), face tournée vers le support de chambre (5), et le support de chambre (5). Le corps de chambre (1) est doté d'une entrée (81) et d'une sortie (82) spatialement séparées l'une de l'autre. Le corps de chambre (1) présente un espace englobant latéralement la puce (2) et entourant un réservoir de gaz (6). Le support de chambre (5) est pourvu de moyens thermiques.
PCT/EP2000/006103 1999-07-02 2000-06-30 Dispositif matrice a microcircuit integre destine a l'amplification et a la caracterisation d'acides nucleiques WO2001002094A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002379125A CA2379125C (fr) 1999-07-02 2000-06-30 Dispositif matrice a microcircuit integre destine a l'amplification et a la caracterisation d'acides nucleiques
EP00952983A EP1192007B1 (fr) 1999-07-02 2000-06-30 Dispositif matrice a microcircuit integre destine a l'amplification et a la caracterisation d'acides nucleiques
AT00952983T ATE264718T1 (de) 1999-07-02 2000-06-30 Microchip-matrix-vorrichtung zur vervielfältigung und charakterisierung von nukleinsäuren
IL14722700A IL147227A0 (en) 1999-07-02 2000-06-30 Microchip matrix device for duplicating and characterizing nucleic acids
AU65599/00A AU768113B2 (en) 1999-07-02 2000-06-30 Microchip matrix device for duplicating and characterizing nucleic acids
DE50006164T DE50006164D1 (de) 1999-07-02 2000-06-30 Microchip-matrix-vorrichtung zur vervielfältigung und charakterisierung von nukleinsäuren
IL147227A IL147227A (en) 1999-07-02 2001-12-20 Microchip matrix device for replication and characterization of nucleic acids
US10/038,284 US7888074B2 (en) 1999-07-02 2002-01-02 Microchip matrix device for duplicating and characterizing nucleic acids
HK02106805.0A HK1046381A1 (zh) 1999-07-02 2002-09-17 用於複製和描述核酸的芯片矩陣裝置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19932423 1999-07-02
DE19932423.9 1999-07-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/038,284 Continuation-In-Part US7888074B2 (en) 1999-07-02 2002-01-02 Microchip matrix device for duplicating and characterizing nucleic acids

Publications (2)

Publication Number Publication Date
WO2001002094A1 true WO2001002094A1 (fr) 2001-01-11
WO2001002094A8 WO2001002094A8 (fr) 2001-06-21

Family

ID=7914426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006103 WO2001002094A1 (fr) 1999-07-02 2000-06-30 Dispositif matrice a microcircuit integre destine a l'amplification et a la caracterisation d'acides nucleiques

Country Status (10)

Country Link
US (1) US7888074B2 (fr)
EP (1) EP1192007B1 (fr)
AT (1) ATE264718T1 (fr)
AU (1) AU768113B2 (fr)
CA (1) CA2379125C (fr)
DE (1) DE50006164D1 (fr)
ES (1) ES2219374T3 (fr)
HK (1) HK1046381A1 (fr)
IL (2) IL147227A0 (fr)
WO (1) WO2001002094A1 (fr)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004699A2 (fr) * 2001-07-06 2003-01-16 Clondiag Chip Technologies Gmbh Procede de mise en evidence de molecules d'acide nucleique amplifiees dans une reaction en chaine de la polymerase
EP1281440A1 (fr) * 2001-07-30 2003-02-05 F. Hoffmann-La Roche Ag Dispositif pour recevoir un support en forme de puces et procédé d'assemblage d'une pluralité de tels dispositifs
WO2003031063A2 (fr) * 2001-10-09 2003-04-17 Clondiag Chip Technologies Gmbh Dispositif destine a maintenir un support de bibliotheque de substances
EP1304166A1 (fr) * 2001-10-19 2003-04-23 GeneScan Europe AG Chambre à écoulement traversant avec chip de détection
WO2003052421A1 (fr) * 2001-12-18 2003-06-26 Motorola, Inc., A Corporation Of The State Of Delaware Dispositif d'analyse electro-chimique dote d'un capteur thermique integre
DE10201463A1 (de) * 2002-01-16 2003-07-24 Clondiag Chip Tech Gmbh Reaktionsgefäß zur Durchführung von Array-Verfahren
DE10338837A1 (de) * 2003-08-21 2004-11-11 Infineon Technologies Ag Verfahren zum Herstellen einer Vorrichtung zur Vervielfältigung und Charakterisierung von Nukleinsäuren sowie Trägerwafer für Biochips
DE10318219A1 (de) * 2003-04-22 2004-11-11 Febit Ag Handhabungs- und Schutzgehäuse für einen Biochip, insbesondere für einen mikrofluidischen Reaktionsträger
DE10316723A1 (de) * 2003-04-09 2004-11-18 Siemens Ag Probenplatte zum Einbau in eine Gehäusestruktur
DE10323197A1 (de) * 2003-05-22 2004-12-23 Clondiag Chip Technologies Gmbh Vorrichtung zur Halterung und Detektion von Substanzbibliotheken
WO2004087951A3 (fr) * 2003-04-02 2005-01-27 Clondiag Chip Tech Gmbh Dispositif de multiplication et d'identification d'acides nucleiques
DE10336849A1 (de) * 2003-08-11 2005-03-10 Thinxxs Gmbh Flusszelle
DE10352888A1 (de) * 2003-11-10 2005-05-04 Infineon Technologies Ag DNA-Chip-Array-Prozessor mit anisotrop elektrisch leitender elastischer Kontaktierung
DE10359160A1 (de) * 2003-12-16 2005-07-21 Roche Diagnostics Gmbh Testelement zur Untersuchung von Probenmaterial
EP1595144A1 (fr) * 2003-02-20 2005-11-16 Capital Biochip Company Ltd Dispositifs en micro-reseau avec volume de reaction reglable
WO2006051088A2 (fr) 2004-11-09 2006-05-18 Clondiag Chip Technologies Gmbh Dispositifs pour executer et analyser des experiences a jeu ordonne de micro-echantillons
WO2009007294A1 (fr) 2007-07-06 2009-01-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Ensemble d'électrodes à membranes
EP2218726A1 (fr) 2001-07-19 2010-08-18 Nanogen Recognomics GmbH Système de triage et d'immobilisation pour acides nucléiques utilisant des systèmes de liaison synthétique
EP2241639A2 (fr) 2004-01-26 2010-10-20 CLONDIAG GmbH Procédé de génotypage et de pathotyage de Pseudomonas aeruginosa
EP2256478A2 (fr) 2004-05-06 2010-12-01 CLONDIAG GmbH Dispositif et procede pour de detecter des interactions moleculaires
EP2330215A1 (fr) 2005-11-04 2011-06-08 CLONDIAG GmbH Procédé et dispositif de détection d'interactions moléculaires
US8293519B2 (en) 2003-08-01 2012-10-23 Capitalbio Corporation Microarray devices having controllable reaction volume
EP2548647A1 (fr) 2006-10-20 2013-01-23 CLONDIAG GmbH Dispositifs et méthodes de dosage destinés à la détection de substances á analyser
EP2610007A1 (fr) 2007-07-23 2013-07-03 CLONDIAG GmbH Tests
EP2644272A1 (fr) 2006-11-06 2013-10-02 CLONDIAG GmbH Dosages
AU2010208085B2 (en) * 2009-01-30 2014-02-06 Gen-Probe Incorporated Systems and methods for detecting a signal and applying thermal energy to a signal transmission element
DE102009061008B4 (de) * 2009-03-20 2014-09-25 Retina Implant Ag Verwendung einer Testvorrichtung und Verfahren zum Test von Zellen, Zellkulturen und/oder organotypischen Zellverbänden
US9199080B2 (en) 2011-09-12 2015-12-01 Okuvision Gmbh Method for treating an eye
US10094802B2 (en) 2016-06-01 2018-10-09 EXIAS Medical GmbH Heating system for a measurement cell
EP3572789A1 (fr) 2005-11-04 2019-11-27 Alere Technologies GmbH Dispositif et procédé de détection de particules
EP3800269A1 (fr) 2014-02-21 2021-04-07 Alere Technologies GmbH Procédés pour détecter plusieurs acides nucléiques dans un échantillon

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677131B2 (en) * 2001-05-14 2004-01-13 Corning Incorporated Well frame including connectors for biological fluids
JP4656057B2 (ja) * 2003-04-10 2011-03-23 株式会社ニコン 液浸リソグラフィ装置用電気浸透素子
EP1541991A1 (fr) * 2003-12-12 2005-06-15 STMicroelectronics S.r.l. Réacteur chimique integré de matériel semiconducteur pour la surveillance des réactions biologiques en temps réel
US8053214B2 (en) * 2004-09-09 2011-11-08 Microfluidic Systems, Inc. Apparatus and method of extracting and optically analyzing an analyte from a fluid-based sample
JP4810093B2 (ja) * 2004-12-28 2011-11-09 オリンパス株式会社 培養観察装置および標本トレー保温装置および蓋
US7858366B2 (en) * 2006-08-24 2010-12-28 Microfluidic Systems, Inc Integrated airborne substance collection and detection system
US7705739B2 (en) * 2006-08-24 2010-04-27 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
DE102007052281A1 (de) * 2007-11-02 2009-05-07 Zenteris Gmbh Einschritt-Multiplex-Immuntest
US10928321B2 (en) 2012-03-09 2021-02-23 Ubiquitome Limited Portable device for detecting molecule(s)
MX350425B (es) 2012-06-28 2017-09-05 Fluoresentric Inc Dispositivo de indicador quimico.
DE102012108158B4 (de) * 2012-09-03 2016-03-17 Johann Wolfgang Goethe-Universität Kapillarzelle, Anordnung und Verfahren zur Aufnahme, zur Positionierung und zur Untersuchung einer mikroskopischen Probe
DE102012219656A1 (de) * 2012-10-26 2014-04-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. System zur durchführung einer berührungslosen messung an einer probe und probenträger
WO2014137228A1 (fr) * 2013-03-08 2014-09-12 Otago Innovation Limited Support de cuve à réaction et dispositif de détection de molécules
CN107076733B (zh) * 2014-09-09 2021-04-30 佩罗斯芬尔技术有限公司 基于微流控芯片的通用凝血测定
FR3038383B1 (fr) * 2015-07-03 2017-07-07 Avalun Appareil d’analyse d’un echantillon liquide comportant un dispositif de blocage et d’ejection
JP6573257B2 (ja) * 2015-09-29 2019-09-11 エア・ウォーター・バイオデザイン株式会社 測定装置及び測定方法
US11092519B1 (en) * 2017-02-06 2021-08-17 Elemental Scientific Lasers, Llc System and method for automated sampling and analysis
DE102019135557A1 (de) * 2019-12-20 2021-06-24 Biophotonics Diagnostics GmbH Probenträger zur elektrischen manipulation von flüssigen proben und zur schwingungsspektroskopie an den proben

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033846A1 (fr) * 1994-06-08 1995-12-14 Affymax Technologies N.V. Appareil de reaction a puce renfermant un groupement de sondes biologiques et sa fabrication
EP0840113A2 (fr) * 1996-10-31 1998-05-06 Shimadzu Corporation Méthode et appareil électrophorétique sur microchip
US5856174A (en) * 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
WO1999009042A2 (fr) * 1997-08-13 1999-02-25 Cepheid Microstructures permettant de manipuler des echantillons fluides
DE19950225A1 (de) * 1998-10-24 2000-05-18 Leica Microsystems Anordnung zur optischen Abtastung eines Objekts
DE19940750A1 (de) * 1998-08-28 2000-06-21 Febit Ferrarius Biotech Gmbh Träger für Analytbestimmungsverfahren und Verfahren zur Herstellung des Trägers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
KR100236506B1 (ko) * 1990-11-29 2000-01-15 퍼킨-엘머시터스인스트루먼츠 폴리머라제 연쇄 반응 수행 장치
US5222808A (en) * 1992-04-10 1993-06-29 Biotrack, Inc. Capillary mixing device
US6521181B1 (en) * 1995-06-20 2003-02-18 The Regents Of The University Of Calfornia Microfabricated electrochemiluminescence cell for chemical reaction detection
CA2250212C (fr) * 1996-04-03 2010-02-09 The Perkin-Elmer Corporation Dispositif et procede de detection d'une pluralite d'analytes
US6054277A (en) * 1996-05-08 2000-04-25 Regents Of The University Of Minnesota Integrated microchip genetic testing system
US5882903A (en) * 1996-11-01 1999-03-16 Sarnoff Corporation Assay system and method for conducting assays
US5922604A (en) * 1997-06-05 1999-07-13 Gene Tec Corporation Thin reaction chambers for containing and handling liquid microvolumes
US6296752B1 (en) * 1998-06-05 2001-10-02 Sarnoff Corporation Apparatus for separating molecules
US6093370A (en) * 1998-06-11 2000-07-25 Hitachi, Ltd. Polynucleotide separation method and apparatus therefor
US6887693B2 (en) * 1998-12-24 2005-05-03 Cepheid Device and method for lysing cells, spores, or microorganisms
US6284195B1 (en) * 1999-01-25 2001-09-04 Industrial Technology Research Institute Disposable reaction module
US6126400A (en) * 1999-02-01 2000-10-03 General Electric Company Thermal barrier coating wrap for turbine airfoil
US6642046B1 (en) * 1999-12-09 2003-11-04 Motorola, Inc. Method and apparatus for performing biological reactions on a substrate surface

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033846A1 (fr) * 1994-06-08 1995-12-14 Affymax Technologies N.V. Appareil de reaction a puce renfermant un groupement de sondes biologiques et sa fabrication
US5856174A (en) * 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0840113A2 (fr) * 1996-10-31 1998-05-06 Shimadzu Corporation Méthode et appareil électrophorétique sur microchip
WO1999009042A2 (fr) * 1997-08-13 1999-02-25 Cepheid Microstructures permettant de manipuler des echantillons fluides
DE19940750A1 (de) * 1998-08-28 2000-06-21 Febit Ferrarius Biotech Gmbh Träger für Analytbestimmungsverfahren und Verfahren zur Herstellung des Trägers
DE19950225A1 (de) * 1998-10-24 2000-05-18 Leica Microsystems Anordnung zur optischen Abtastung eines Objekts

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004699A3 (fr) * 2001-07-06 2003-04-24 Clondiag Chip Tech Gmbh Procede de mise en evidence de molecules d'acide nucleique amplifiees dans une reaction en chaine de la polymerase
WO2003004699A2 (fr) * 2001-07-06 2003-01-16 Clondiag Chip Technologies Gmbh Procede de mise en evidence de molecules d'acide nucleique amplifiees dans une reaction en chaine de la polymerase
EP2298929A1 (fr) 2001-07-19 2011-03-23 Nanogen Recognomics GmbH Système de triage et d'immobilisation pour acides nucléiques utilisant des systèmes de liaison synthétique
EP2218726A1 (fr) 2001-07-19 2010-08-18 Nanogen Recognomics GmbH Système de triage et d'immobilisation pour acides nucléiques utilisant des systèmes de liaison synthétique
EP1955769A3 (fr) * 2001-07-30 2008-08-20 F.Hoffmann-La Roche Ag Procédé de positionnement et de fixation d'un deuxième objet sur un premier
EP1281440A1 (fr) * 2001-07-30 2003-02-05 F. Hoffmann-La Roche Ag Dispositif pour recevoir un support en forme de puces et procédé d'assemblage d'une pluralité de tels dispositifs
EP1281439A1 (fr) * 2001-07-30 2003-02-05 F. Hoffmann-La Roche Ag Dispositif pour recevoir un support en forme de puces et procédé d'assemblage d' une pluralité de tels dispositifs
US6756224B2 (en) 2001-07-30 2004-06-29 Roche Molecular Systems, Inc. Device for receiving a chip shaped carrier and process for assembling a plurality of such devices
EP1671698A3 (fr) * 2001-10-09 2006-11-02 Clondiag Chip Technologies GmbH Dispositif destiné a maintenir un support de bibliothèque de substances
WO2003031063A3 (fr) * 2001-10-09 2003-09-12 Clondiag Chip Tech Gmbh Dispositif destine a maintenir un support de bibliotheque de substances
DE10149684B4 (de) * 2001-10-09 2005-02-17 Clondiag Chip Technologies Gmbh Vorrichtung zur Halterung eines Substanzbibliothekenträgers
EP1671698A2 (fr) * 2001-10-09 2006-06-21 Clondiag Chip Technologies GmbH Dispositif destiné a maintenir un support de bibliothèque de substances
DE10149684A1 (de) * 2001-10-09 2003-04-24 Clondiag Chip Tech Gmbh Vorrichtung zur Halterung eines Substanzbibliothekenträgers
WO2003031063A2 (fr) * 2001-10-09 2003-04-17 Clondiag Chip Technologies Gmbh Dispositif destine a maintenir un support de bibliotheque de substances
EP1304166A1 (fr) * 2001-10-19 2003-04-23 GeneScan Europe AG Chambre à écoulement traversant avec chip de détection
WO2003052421A1 (fr) * 2001-12-18 2003-06-26 Motorola, Inc., A Corporation Of The State Of Delaware Dispositif d'analyse electro-chimique dote d'un capteur thermique integre
US6756223B2 (en) 2001-12-18 2004-06-29 Motorola, Inc. Electro-chemical analysis device with integrated thermal sensor and method for monitoring a sample using the device
DE10201463B4 (de) * 2002-01-16 2005-07-21 Clondiag Chip Technologies Gmbh Reaktionsgefäß zur Durchführung von Array-Verfahren
EP1642644A1 (fr) 2002-01-16 2006-04-05 Clondiag Chip Technologies GmbH Appareil de détection des molecules ciblées
EP2210665A1 (fr) 2002-01-16 2010-07-28 CLONDIAG GmbH Appareil de détection des molecules ciblées
DE10201463A1 (de) * 2002-01-16 2003-07-24 Clondiag Chip Tech Gmbh Reaktionsgefäß zur Durchführung von Array-Verfahren
EP1595144A4 (fr) * 2003-02-20 2008-04-02 Capitalbio Corp Dispositifs en micro-reseau avec volume de reaction reglable
EP1595144A1 (fr) * 2003-02-20 2005-11-16 Capital Biochip Company Ltd Dispositifs en micro-reseau avec volume de reaction reglable
US7767438B2 (en) 2003-02-20 2010-08-03 Capitalbio Corporation Microarray devices having controllable reaction volume
WO2004087951A3 (fr) * 2003-04-02 2005-01-27 Clondiag Chip Tech Gmbh Dispositif de multiplication et d'identification d'acides nucleiques
EP2266699A1 (fr) 2003-04-02 2010-12-29 CLONDIAG GmbH Appareil pour l'amplification et la détection d'acide nucléique
DE10316723A1 (de) * 2003-04-09 2004-11-18 Siemens Ag Probenplatte zum Einbau in eine Gehäusestruktur
DE10318219A1 (de) * 2003-04-22 2004-11-11 Febit Ag Handhabungs- und Schutzgehäuse für einen Biochip, insbesondere für einen mikrofluidischen Reaktionsträger
DE10323197A1 (de) * 2003-05-22 2004-12-23 Clondiag Chip Technologies Gmbh Vorrichtung zur Halterung und Detektion von Substanzbibliotheken
DE10323197B4 (de) * 2003-05-22 2008-10-02 Clondiag Chip Technologies Gmbh Vorrichtung zur Halterung und Detektion von Substanzbibliotheken
US8293519B2 (en) 2003-08-01 2012-10-23 Capitalbio Corporation Microarray devices having controllable reaction volume
US7595871B2 (en) 2003-08-11 2009-09-29 Thinxxs Microtechnology Ag Flow cell consisting of layer and connection means
DE10336849A1 (de) * 2003-08-11 2005-03-10 Thinxxs Gmbh Flusszelle
DE10338837A1 (de) * 2003-08-21 2004-11-11 Infineon Technologies Ag Verfahren zum Herstellen einer Vorrichtung zur Vervielfältigung und Charakterisierung von Nukleinsäuren sowie Trägerwafer für Biochips
DE10352888A1 (de) * 2003-11-10 2005-05-04 Infineon Technologies Ag DNA-Chip-Array-Prozessor mit anisotrop elektrisch leitender elastischer Kontaktierung
DE10359160A1 (de) * 2003-12-16 2005-07-21 Roche Diagnostics Gmbh Testelement zur Untersuchung von Probenmaterial
EP2241639A2 (fr) 2004-01-26 2010-10-20 CLONDIAG GmbH Procédé de génotypage et de pathotyage de Pseudomonas aeruginosa
EP2280267A2 (fr) 2004-05-06 2011-02-02 CLONDIAG GmbH Dispositif et procédé pour de detecter des interactions moleculaires
EP3527287A1 (fr) 2004-05-06 2019-08-21 Alere Technologies GmbH Procéde pour de détecter des interactions moléculaires
EP2290351A2 (fr) 2004-05-06 2011-03-02 CLONDIAG GmbH Dispositif et procédé pour détecter des interactions moléculaires
EP3171155A1 (fr) 2004-05-06 2017-05-24 Clondiag GmbH Dispositif et procede pour de detecter des interactions moleculaires
EP2256478A2 (fr) 2004-05-06 2010-12-01 CLONDIAG GmbH Dispositif et procede pour de detecter des interactions moleculaires
EP2299257A2 (fr) 2004-05-06 2011-03-23 CLONDIAG GmbH Dispositif et procédé pour détecter des interactions moléculaires
WO2006051088A2 (fr) 2004-11-09 2006-05-18 Clondiag Chip Technologies Gmbh Dispositifs pour executer et analyser des experiences a jeu ordonne de micro-echantillons
EP2305383A1 (fr) 2004-11-09 2011-04-06 CLONDIAG GmbH Dispositifs pour executer et analyser des experiences a jeu ordonne de micro-echantillons
EP3572789A1 (fr) 2005-11-04 2019-11-27 Alere Technologies GmbH Dispositif et procédé de détection de particules
EP2330215A1 (fr) 2005-11-04 2011-06-08 CLONDIAG GmbH Procédé et dispositif de détection d'interactions moléculaires
EP2548647A1 (fr) 2006-10-20 2013-01-23 CLONDIAG GmbH Dispositifs et méthodes de dosage destinés à la détection de substances á analyser
EP2644272A1 (fr) 2006-11-06 2013-10-02 CLONDIAG GmbH Dosages
EP2674217A2 (fr) 2006-11-06 2013-12-18 CLONDIAG GmbH Dosages
WO2009007294A1 (fr) 2007-07-06 2009-01-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Ensemble d'électrodes à membranes
EP2610007A1 (fr) 2007-07-23 2013-07-03 CLONDIAG GmbH Tests
EP2647432A1 (fr) 2007-07-23 2013-10-09 CLONDIAG GmbH Tests
US9925536B2 (en) 2007-07-23 2018-03-27 Clondiag Gmbh Assays for measuring nucleic acids
EP2626434A1 (fr) 2007-07-23 2013-08-14 CLONDIAG GmbH Tests
EP3527288A1 (fr) 2007-07-23 2019-08-21 Alere Technologies GmbH Procédé de détection de virus
EP2612708A1 (fr) 2007-07-23 2013-07-10 CLONDIAG GmbH Tests
AU2010208085B2 (en) * 2009-01-30 2014-02-06 Gen-Probe Incorporated Systems and methods for detecting a signal and applying thermal energy to a signal transmission element
DE102009061008B4 (de) * 2009-03-20 2014-09-25 Retina Implant Ag Verwendung einer Testvorrichtung und Verfahren zum Test von Zellen, Zellkulturen und/oder organotypischen Zellverbänden
US9162060B2 (en) 2009-03-20 2015-10-20 Retina Implant Ag Active retinal implant
US9199080B2 (en) 2011-09-12 2015-12-01 Okuvision Gmbh Method for treating an eye
EP3800269A1 (fr) 2014-02-21 2021-04-07 Alere Technologies GmbH Procédés pour détecter plusieurs acides nucléiques dans un échantillon
US10094802B2 (en) 2016-06-01 2018-10-09 EXIAS Medical GmbH Heating system for a measurement cell

Also Published As

Publication number Publication date
AU6559900A (en) 2001-01-22
EP1192007A1 (fr) 2002-04-03
US7888074B2 (en) 2011-02-15
CA2379125A1 (fr) 2001-01-11
IL147227A (en) 2006-08-20
CA2379125C (fr) 2009-04-07
ATE264718T1 (de) 2004-05-15
IL147227A0 (en) 2002-08-14
EP1192007B1 (fr) 2004-04-21
DE50006164D1 (de) 2004-05-27
AU768113B2 (en) 2003-12-04
HK1046381A1 (zh) 2003-01-10
ES2219374T3 (es) 2004-12-01
US20020150933A1 (en) 2002-10-17
WO2001002094A8 (fr) 2001-06-21

Similar Documents

Publication Publication Date Title
EP1192007B1 (fr) Dispositif matrice a microcircuit integre destine a l'amplification et a la caracterisation d'acides nucleiques
KR101544351B1 (ko) 유기체의 게놈 ｄｎａ를 확인하기 위한 장치 및 방법
US10876174B2 (en) Method for the detection and characterization of a toxinogenic Clostridium difficile strain
EP2809803B1 (fr) Pcr numérique multiplexée
US9416418B2 (en) Biochip and target DNA quantitative method
Liu et al. Rapid antimicrobial susceptibility testing with electrokinetics enhanced biosensors for diagnosis of acute bacterial infections
MXPA05004470A (es) Sistema microfluidico que utiliza capas de pelicula delgada para dirigir fluidos.
US20140295424A1 (en) Isolation and Enrichment of Nucleic Acids on Microchip
US20150322515A1 (en) Methods and compositions for detecting target snp
EP2337633B1 (fr) Dispositif permettant de mettre en uvre une pcr
EP3558525B1 (fr) Systèmes d'extraction et de pcr combinés
CN108291251A (zh) 用于核酸分析的系统和方法
US11015218B2 (en) Method, microreactor and apparatus for carrying out real-time nucleic acid amplification
DE102014221616A1 (de) Mikrofluidische Vorrichtung sowie Verfahren zum Analysieren einer Probe biologischen Materials
WO2014078521A1 (fr) Isolement et enrichissement d'acides nucléiques sur micropuce
WO2010022417A1 (fr) Dispositif pour porter à l'équilibre de température un récipient à symétrie de rotation
RU2386698C1 (ru) Способ идентификации трансгенных последовательностей днк в растительном материале и продуктах на его основе
Martzy et al. Challenges and perspectives for isothermal DNA amplification methods in food and water analysis
Auroux Detection of Pathogens by On-Chip PCR

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM DZ EE GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LV MA MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM DZ EE GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LV MA MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2379125

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10038284

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000952983

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 65599/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000952983

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 65599/00

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2000952983

Country of ref document: EP